|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| C07K 16/30 | |||
| A61P 35/00 | |||
| A61K 47/68 |
| (11) | Patento numeris | 3383909 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16819220.1 |
| Europos patento paraiškos padavimo data | 2016-11-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-10-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-06-17 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/063990 |
| Data | 2016-11-29 |
| (87) | Numeris | WO 2017/095805 |
| Data | 2017-06-08 |
| (30) | Numeris | Data | Šalis |
| 201562261092 P | 2015-11-30 | US | |
| 201662417480 P | 2016-11-04 | US |
| (72) |
GISH, Kurt C., US
HICKSON, Jonathan A., US
PURCELL, James W., US
MORGAN-LAPPE, Susan Elizabeth, US
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
AbbVie Biotherapeutics Inc., 1500 Seaport Boulevard, Redwood City, CA 94063, US |
| (54) | ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |